@article {Bartholomew39, author = {John R. Bartholomew}, title = {Update on the management of venous thromboembolism}, volume = {84}, number = {12 suppl 3}, pages = {39--46}, year = {2017}, doi = {10.3949/ccjm.84.s3.04}, publisher = {Cleveland Clinic Journal of Medicine}, abstract = {Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, is a common cardiovascular disease associated with significant morbidity ranging from painful leg swelling, chest pain, shortness of breath, and even death. Long-term complications include recurrent VTE, postpulmonary embolism syndrome, chronic thromboembolic pulmonary hypertension, and postthrombotic syndrome (PTS). Management of VTE requires immediate anticoagulation therapy based on a risk assessment for bleeding. Direct oral anticoagulants (DOACs) have become an important option for patients as reflected in the most recent American College of Chest Physician treatment guidelines.}, issn = {0891-1150}, URL = {https://www.ccjm.org/content/84/12_suppl_3/39}, eprint = {https://www.ccjm.org/content/84/12_suppl_3/39.full.pdf}, journal = {Cleveland Clinic Journal of Medicine} }